CHRONIC GRAFT-VERSUS-HOST-DISEASE
Clinical trials for CHRONIC GRAFT-VERSUS-HOST-DISEASE explained in plain language.
Never miss a new study
Get alerted when new CHRONIC GRAFT-VERSUS-HOST-DISEASE trials appear
Sign up with your email to follow new studies for CHRONIC GRAFT-VERSUS-HOST-DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could an arthritis drug tame a tough transplant complication?
Disease control CompletedThis study tests the drug abatacept in people with chronic graft-versus-host disease (cGVHD) that is not controlled by steroids. cGVHD is a condition where donor immune cells attack the recipient's body after a stem cell transplant. The trial has two phases: first, to find a safe…
Matched conditions: CHRONIC GRAFT-VERSUS-HOST-DISEASE
Phase: PHASE1, PHASE2 • Sponsor: Beth Israel Deaconess Medical Center • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for teens with chronic Graft-Versus-Host disease: belumosudil under study
Disease control CompletedThis study tested the drug belumosudil in Chinese teenagers aged 12 to 18 with chronic graft-versus-host disease (cGVHD), a complication after stem cell transplant. The goal was to see how well the drug works and how safe it is for those who didn't respond to steroids. Six partic…
Matched conditions: CHRONIC GRAFT-VERSUS-HOST-DISEASE
Phase: PHASE4 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New combo therapy shows promise for tough transplant complication
Disease control CompletedThis study tested adding a low dose of the drug Interleukin-2 (IL-2) to a standard therapy called extracorporeal photopheresis (ECP) for people with chronic graft-versus-host disease (GVHD) that did not respond to steroids. Chronic GVHD is a serious condition where donor immune c…
Matched conditions: CHRONIC GRAFT-VERSUS-HOST-DISEASE
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New hope for GVHD patients: nilotinib steps in when imatinib fails
Disease control CompletedThis study tested the drug nilotinib in 65 adults with chronic graft-versus-host disease (GVHD) who did not respond to imatinib. GVHD is a complication after a stem cell transplant where donor cells attack the patient's body. The goal was to see if nilotinib could help control th…
Matched conditions: CHRONIC GRAFT-VERSUS-HOST-DISEASE
Phase: PHASE2 • Sponsor: University Hospital, Lille • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New drug combo shows promise for kids with transplant complication
Disease control CompletedThis study tested whether adding the drug ruxolitinib to standard steroids helps children with chronic graft-versus-host disease (cGVHD), a complication after stem cell transplants. 46 children aged 28 days to 18 years took part. The main goal was to see how many had a complete o…
Matched conditions: CHRONIC GRAFT-VERSUS-HOST-DISEASE
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Could a cancer drug ease a devastating transplant complication in kids?
Disease control CompletedThis study tested the drug ibrutinib in 59 children with chronic graft-versus-host disease (cGVHD), a serious condition that can occur after a stem cell transplant. The goal was to find the best dose and see if it is safe. Participants had moderate or severe cGVHD that did not im…
Matched conditions: CHRONIC GRAFT-VERSUS-HOST-DISEASE
Phase: PHASE1, PHASE2 • Sponsor: Pharmacyclics LLC. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New hope for tough GvHD: pomalidomide shows promise in small trial
Disease control CompletedThis study tested a drug called pomalidomide in 34 adults with chronic graft-versus-host disease (GvHD) that didn't improve with standard treatments. GvHD can happen after a stem cell transplant when the donor cells attack the recipient's body. Participants took pomalidomide caps…
Matched conditions: CHRONIC GRAFT-VERSUS-HOST-DISEASE
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New antibody shows promise for Hard-to-Treat GVHD
Disease control CompletedThis trial tested a drug called axatilimab in 41 people with chronic graft-versus-host disease (cGVHD), a complication of stem cell transplants where donor cells attack the patient's body. Participants had already tried at least two other treatments. The study aimed to find a saf…
Matched conditions: CHRONIC GRAFT-VERSUS-HOST-DISEASE
Phase: PHASE1, PHASE2 • Sponsor: Syndax Pharmaceuticals • Aim: Disease control
Last updated Jun 26, 2026 17:19 UTC
-
Scientists track mouth health to unlock secrets of transplant complication
Knowledge-focused CompletedThis study followed 190 adults who had or were about to have a stem cell transplant from a donor. Researchers tracked changes in the mouth, like dryness or sores, to learn more about chronic graft-versus-host disease (cGVHD). Participants provided saliva, mouth swabs, and had den…
Matched conditions: CHRONIC GRAFT-VERSUS-HOST-DISEASE
Sponsor: National Institute of Dental and Craniofacial Research (NIDCR) • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC